Topical application of imiquimod (TLR7 agonist) or resiquimod (TLR7/8 agonist) has been used successfully to treat several murine tumor models [15–17], while resiquimod has also demonstrated efficacy in early-stage cutaneous T-cell lymphoma [18]. Here, TLR7 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.